Janssen Scientific Affairs has introduced JanssenMD, a new medical information tool for accessing drug information and clinical resources through desktops, tablets, and smartphones in the US.

The new web-based application and online scientific resource is designed to enable access to current information about Janssen products marketed in the US.

Janssen Scientific Affairs chief scientific officer Dr. Norm Rosenthal said JanssenMD was created to provide healthcare professionals with the information they need, when, where, and how they need it.

"This unique digital platform enables us to respond to healthcare professionals’ questions with information that is current, accurate, and instantly accessible from any device they are using," Dr. Rosenthal added.

JanssenMD’s search functionality enables clinicians to identify full prescribing information, clinical trial data, and safety information about Janssen medications.

The company claims that it is the among the first medical information websites to offer a self-service model that is accessible through mobile devices.

Besides product information, the web-based application provides access to Janssen prescription assistance programmes and risk evaluation and mitigation tools.

At present, JanssenMD provides scientific information for five pharmaceutical products Edurant (rilpivirine), Remicade (infliximab), Stelara (ustekinumab), Xarelto (rivaroxaban), and Zytiga (abiraterone acetate); additional Janssen products will be added over time.